€2 billion revenue
(approx. 241.6 billion yen)

93% of revenue from prescription ophthalmic pharmaceuticals 

Sales outside Japan account for 31.7% of corporate revenue

4,108 employees globally

Products supplied in over 60 countries 

Dedicated facilities for ongoing research and development: Nara (Japan), RIKEN-Santen Joint Laboratory (Japan), Santen-SERI OpeN Innovation Center (Singapore), Tampere (Finland), Evry (France), Emeryville (US)

Three manufacturing sites: Noto and Shiga (Japan), Suzhou (China)